| KUMAR S K, RAJKUMAR V, KYLE R A, et al. Multiple myelomal[J]. Nat Rev Dis Primers, 2017, 20(7): 17043-17046. |
| HAMED R A, BAZARBACHI A H, MALARD F, et al. Current Status of Autologous Stem Cell Transplantation for Multiple Myeloma[J]. Blood Cancer Journal, 2019, 9(4): 44-48. doi: 10.1038/s41408-019-0205-9 |
| JIMÉNEZ-SEGURA R, GRANELL M, GIRONELLA M, et al. Pomalidomide-dexamethasone for Treatment of Soft-tissue Plasmacytomas in Patients with Relapsed / Refractory Multiple Myeloma[J]. European Journal of Haematology, 2019, 102(5): 389-394. doi: 10.1111/ejh.13217 |
| LAUBACH J, GARDERET L, MAHINDRA A, et al. Management of Relapsed Multiple Myeloma: Recommendations of the International Myeloma Working Group[J]. Leukemia, 2016, 30(5): 1005-1017. doi: 10.1038/leu.2015.356 |
| SAFARI E, GHORGHANLU S, AHMADI-KHIAVI H, et al. Myeloid-derived Suppressor Cells and Tumor: Current Knowledge and Future Perspectives[J]. Journal of Cellular Physiology, 2019, 234(7): 9966-9981. doi: 10.1002/jcp.27923 |
| HEINHUIS B, KOENDERS M I, VAN DEN BERG W B, et al. Interleukin 32 (IL-32) Contains a Typical α-Helix Bundle Structure that Resembles Focal Adhesion Targeting Region of Focal Adhesion Kinase-1[J]. Journal of Biological Chemistry, 2012, 287(8): 5733-5743. doi: 10.1074/jbc.M111.288290 |
| KHAWAR M B, ABBASI M H, SHEIKH N. IL-32: a Novel Pluripotent Inflammatory Interleukin, towards Gastric Inflammation, Gastric Cancer, and Chronic Rhino Sinusitis[J]. Mediators of Inflammation, 2016, 6(4): 8413768. |
| 邹美银, 章幼奕, 朱勇根, 等. 乙肝病毒相关肝细胞肝癌与IL-32表达相关性研究[J]. 中华肿瘤防治杂志, 2017, 24(12): 835-838, 844. |
| 杨正斌, 马川, 牟辉. 肺癌患者癌组织及癌旁组织中IL-32、Foxp3、CXCL8的表达水平及意义[J]. 临床肺科杂志, 2018, 23(9): 1578-1583. doi: 10.3969/j.issn.1009-6663.2018.09.007 |
| 谷月丽, 肖喜春, 杨硕. 多发性骨髓瘤患者血浆白介素16水平的变化及临床意义[J]. 中国实验血液学杂志, 2017, 25(3): 823-826. |
| AVET-LOISEAU H, DURIE B G M, CAVO M, et al. Combining Fluorescent in Situ Hybridization Data with ISS Staging Improves Risk Assessment in Myeloma: an International Myeloma Working Group Collaborative Project[J]. Leukemia, 2013, 27(3): 711-717. doi: 10.1038/leu.2012.282 |
| 吴晓颖, 施菊妹, 陶怡, 等. IGF-I、β2-MG和SF在多发性骨髓瘤患者中的诊断价值及其临床分期的关系[J]. 中国实验血液学杂志, 2018, 26(3): 802-806. |
| 金晓娜, 周宝珍, 张党锋. 多发性骨髓瘤患者VEGF、IL-17、β2-MG、IL-35表达水平及临床意义[J]. 中国实验血液学杂志, 2018, 26(1): 192-196. |
| 中国医师协会血液科医师分会, 中华医学会血液学分会, 中国医师协会多发性骨髓瘤专业委员会. 中国多发性骨髓瘤诊治指南(2015年修订)[J]. 中华内科杂志, 2015, 54(12): 1066-1070. doi: 10.3760/cma.j.issn.0578-1426.2015.12.020 |
| VICTOR M, EVGENIY H, GERGANA T, et al. Serum Hepcidin Levels in Multiple Myeloma[J]. Clinical Laboratory, 2017, 63(7): 1273-1277. |
| KUMAR S, PAIVA B, ANDERSON KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma[J]. Lancet Oncol, 2016, 17(8): 328-346. doi: 10.1016/S1470-2045(16)30206-6 |
| MCCARTHY P L, PALUMBO A. Maintenance Therapy for Multiple Myeloma[J]. Hematology/Oncology Clinics of North America, 2014, 28(5): 839-859. doi: 10.1016/j.hoc.2014.06.006 |
| PERWEZ H S, HARRIS C C. Inflammation and Cancer: an Ancient Link with Novel Potentials[J]. International Journal of Cancer, 2007, 121(11): 2373-2380. doi: 10.1002/ijc.23173 |
| CHEN Q, CARROLL H P, GADINA M. The Newest Interleukins: Recent Additions to the Ever-Growing Cytokine Family[J]. 2006, 74: 207-228. |
| MONIGATTI F, HEKKING B, STEEN H. Protein Sulfation Analysis——A Primer[J]. Biochimica et Biophysica Acta, 2006, 1764(12): 1904-1913. doi: 10.1016/j.bbapap.2006.07.002 |
| JIA L, CLEAR A, LIU F T, et al. Extracellular HMGB1 Promotes Differentiation of Nurse-like Cells in Chronic Lymphocytic Leukemia[J]. Blood, 2014, 123(11): 1709-1719. doi: 10.1182/blood-2013-10-529610 |
| YANG Y, WANG Z H, ZHOU Y M, et al. Dysregulation of Over-expressed IL-32 in Colorectal Cancer Induces Metastasis[J]. World Journal of Surgical Oncology, 2015, 13(4): 143-146. |
| PHAM T H, BAK Y, KWON T, et al. Interleukin-32θ Inhibits Tumor-promoting Effects of Macrophage-secreted CCL18 in Breast Cancer[J]. Cell Communication and Signaling, 2019, 17: 53-57. doi: 10.1186/s12964-019-0374-y |
| WANG G, NING F Y, WANG J H, et al. Expression of Interleukin-32 in Bone Marrow of Patients with Myeloma and Its Prognostic Significance[J]. World Journal of Clinical Cases, 2019, 7(24): 4234-4244. doi: 10.12998/wjcc.v7.i24.4234 |
| ZAHOOR M, WESTHRIN M, AASS K R, et al. Hypoxia Promotes IL-32 Expression in Myeloma Cells, and High Expression is Associated with Poor Survival and Bone Loss[J]. Blood Advances, 2017, 1(27): 2656-2666. doi: 10.1182/bloodadvances.2017010801 |
| GUPTA N, SHARMA A, SHARMA A. Emerging Biomarkers in Multiple Myeloma: a Review[J]. Clinica Chimica Acta, 2020, 503: 45-53. doi: 10.1016/j.cca.2019.12.026 |
| CHAE H, RYU H, CHA K, et al. Neutrophil Gelatinase-Associated Lipocalin as a Biomarker of Renal Impairment in Patients with Multiple Myeloma[J]. Clinical Lymphoma Myeloma and Leukemia, 2015, 15(1): 35-40. doi: 10.1016/j.clml.2014.07.014 |
| 宋斌, 陈雁, 张荣耀, 等. 血清CysC、Cr及LDH水平变化诊断多发性骨髓瘤早期肾损伤的价值[J]. 现代肿瘤医学, 2018, 26(21): 3471-3474. doi: 10.3969/j.issn.1672-4992.2018.21.031 |
| 张蕴玉, 彭静, 宋志刚, 等. 胱抑素C与β2-微球蛋白在多发性骨髓瘤病情及近期疗效评估中的应用[J]. 国际肿瘤学杂志, 2019, 46(10): 590-594. doi: 10.3760/cma.j.issn.1673-422X.2019.10.004 |